Clinical Trial Update: A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial comparing Procrit (epoetin alfa) versus no Procrit in patients with acute myeloid leukemia and high-risk myelodysplastic syndromes; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2013-12-23